Cystic fibrosis drug PBS listed

THE Health Department has announced Pharmaceutical Benefits Scheme (PBS) funding for the cycstic fibrosis therapy Kalydeco (ivacaftor) sponsored by Vertex Pharmaceuticals.

Infants aged 12 to 24 months with the diagnosis will be eligible, saving their families up to $300,000 per year, and helping respiratory function.

Health Minister Greg Hunt also announced other PBS listings.

See the full list at health.gov.au.